Use code TPM for up to 66% off at MyPillow.com

ADVERTISEMENT

New Israeli COVID treatment shows promising results in phase 2 trials

The Israeli company Enlivex Therapeutics announced the trial results for their drug Allocetra on Wednesday.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

A new treatment from Israel for patients suffering from severe cases of coronavirus has shown promising results in the second phase of clinical trials, Algemeiner reports.

The trial, however, was only conducted on 16 patients, nine of whom were in serious condition, while the other seven were in critical condition. Despite the small sample size, the researchers were happy to note that none of the patients had succumbed to the virus, and 14 of the 16 patients were discharged from hospital.

The Israeli company Enlivex Therapeutics announced the trial results for their drug, Allocetra, on Wednesday. They had previously conducted a phase one trial on just five patients, all of whom recovered after taking the medication.

Allocetra is a drug designed to prevent the immune system from overreacting to the presence of a virus, which can sometimes cause more damage to the human body than the actual virus infecting it.

As the coronavirus vaccine is being rolled out around the world, some priority is still being placed on developing effective treatments for those who have contracted and are suffering from the virus.

Enlivex says they will be submitting the drug to regulatory bodies in Europe and North America for further trials.

ADVERTISEMENT
ADVERTISEMENT
N/A by N/A is licensed under N/A

Join and support independent free thinkers!

We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.

Support The Post Millennial

Remind me in September

We will use this to send you a single email in September 2020. To find out what personal data we collect and how we use it, please visit our Privacy Policy

ADVERTISEMENT
ADVERTISEMENT
By signing up you agree to our Terms of Use and Privacy Policy
ADVERTISEMENT
© 2022 The Post Millennial, Privacy Policy